The pharmacological mechanisms of omalizumab in patients with very high IgE levels—Clues from studies on atopic dermatitis
作者： Tse Wen Chang , Jiun-Bo Chen , Chia-Yu Chu
DOI: 10.1016/J.DSI.2012.10.001
关键词: Omalizumab 、 Product Label 、 Immunology 、 Serum ige 、 Dermatology 、 In patient 、 Medicine 、 Immunoglobulin E 、 Atopic dermatitis
摘要: Abstract Seventeen case series investigating the effects of omalizumab on patients with atopic dermatitis included whose pretreatment serum IgE was above 700 IU/ml, upper inclusion limit specified in product label. In all, 107 received at doses ≤375 mg every 2 weeks, which is recommended for
core.ac.uk
sci-hub.se 参考文章(65)
J Gómez Vera, J López Tiro, E Contreras Contreras, M E Ramírez del Pozo, Omalizumab (an anti-IgE antibody) in the treatment of severe atopic eczema. Journal of Investigational Allergology and Clinical Immunology. ,vol. 21, pp. 416- 417 ,(2011)
C. Incorvaia, C. Pravettoni, M. Mauro, M.-R. Yacoub, F. Tarantini, G.G. Riario-Sforza, Effectiveness of omalizumab in a patient with severe asthma and atopic dermatitis. Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace / Fondazione clinica del lavoro, IRCCS [and] Istituto di clinica tisiologica e malattie apparato respiratorio, Università di Napoli, Secondo ateneo. ,vol. 69, pp. 78- 80 ,(2008) , 10.4081/MONALDI.2008.401
David Amrol, Anti-immunoglobulin e in the treatment of refractory atopic dermatitis. Southern Medical Journal. ,vol. 103, pp. 554- 558 ,(2010) , 10.1097/SMJ.0B013E3181DE0CF6
Peter Maximilian Heil, Dieter Maurer, Brigitte Klein, Thomas Hultsch, Georg Stingl, Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course - a randomized, placebo-controlled and double blind pilot study JDDG: Journal der Deutschen Dermatologischen Gesellschaft. ,vol. 8, pp. 990- 998 ,(2010) , 10.1111/J.1610-0387.2010.07497.X
Tse Wen Chang, Pheidias C. Wu, C. Long Hsu, Alfur F. Hung, Anti‐IgE Antibodies for the Treatment of IgE‐Mediated Allergic Diseases Advances in Immunology. ,vol. 93, pp. 63- 119 ,(2007) , 10.1016/S0065-2776(06)93002-8
Algin B. Garrett, Seth B. Forman, Success of omalizumab as monotherapy in adult atopic dermatitis: case report and discussion of the high-affinity immunoglobulin E receptor, FcepsilonRI. Cutis. ,vol. 80, pp. 38- 40 ,(2007)
Philip J. Lowe, Didier Renard, Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE British Journal of Clinical Pharmacology. ,vol. 72, pp. 306- 320 ,(2011) , 10.1111/J.1365-2125.2011.03962.X
Sherry A. Sterbinsky, Daniel C. Adelman, Sarbjit S. Saini, Donald W. Macglashan, Bruce S. Bochner, Lawrence M. Lichtenstein, Alkis Togias, Down-Regulation of Human Basophil IgE and FCεRIα Surface Densities and Mediator Release by Anti-IgE-Infusions Is Reversible In Vitro and In Vivo Journal of Immunology. ,vol. 162, pp. 5624- 5630 ,(1999)
A. Groffik, H. Mitzel-Kaoukhov, M. Magerl, M. Maurer, P. Staubach, Omalizumab – an effective and safe treatment of therapy‐resistant chronic spontaneous urticaria Allergy. ,vol. 66, pp. 303- 305 ,(2011) , 10.1111/J.1398-9995.2010.02472.X
F. Toledo, J.F. Silvestre, C. Muñoz, Combined therapy with low-dose omalizumab and intravenous immunoglobulin for severe atopic dermatitis. Report of four cases. Journal of The European Academy of Dermatology and Venereology. ,vol. 26, pp. 1325- 1327 ,(2012) , 10.1111/J.1468-3083.2011.04326.X